The Muhimbili Sickle Cohort was started in 2004 with a 4-year Wellcome Trust training fellowship awarded to Dr. Julie Makani to conduct research in Sickle Cell Disease (SCD), at the Muhimbili National Hospital (MNH) and Muhimbili University of Health and Allied Sciences (MUHAS) in Dar-es-salaam.
This randomized, double blind cross-over trial is designed to test two major endpoints:(1) can a twice daily ready-to-use supplementary food (RUSF) fortified with high levels of the amino acids arginine and citrulline (RUSF-v) plus daily
Tanzania has one of the highest annual births of Sickle Cell Disease (SCD) affected individuals in the world, estimated to be between 8,000 to 11,000 births year. Without interventions, up to 90% of affected
The study is measuring whole body (systemic) nitric oxide (NO) production in Tanzanian children with sickle cell disease (SCD).
Call the Sickle Cell Clinic